Petosemtamab
Based on 1 Customer Validation
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.90%
- No. CAS: 2213450-26-9
- Peso molecular:145.5 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas EGFR
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[2]|
EGFR 0.22 nM (Kd) |
LGR5 0.85 nM (Kd) |
In Vitro
Petosemtamab (MCLA 158) (1 µg/mL, 24 or 72 h) leads to EGFR degradation in EGFR+/LGR5+ colorectal cancer organoids[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids
-
Concentration:1 µg/mL
-
Incubation Time:1, 6, 24, 72 h
-
Result:Time-dependently degraded EGFR.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2]
-
Dosage:25 mg/kg/week
-
Administration:Intravenous injection (i.v.) for 6 weeks.
-
Result:Inhibited tumor growth.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized EGFR Protein, Human (621a.a, CHO, His, HY-P7340) can bind Petosemtamab. The EC50 for this effect is 4.45 ng/mL. -
Immobilized HY-P79308 Lgr5/GPR49 Protein, Human (CHO, hFc) can bind Petosemtamab. The EC50 for this effect is 85 ng/mL.
Chemical Information
-
No. CAS 2213450-26-9
-
Appearance Liquid
-
Peso molecular 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Petosemtamab]
-
Synonyms
MCLA 158
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)